Lanthanum Carbonate Patent Expiration
Lanthanum Carbonate is Used for lowering serum phosphate levels in patients with end stage renal disease. It was first introduced by Takeda Pharmaceuticals Usa Inc
Lanthanum Carbonate Patents
Given below is the list of patents protecting Lanthanum Carbonate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Fosrenol | US5968976 | Pharmaceutical composition containing selected lanthanum carbonate hydrates |
Oct 26, 2018
(Expired) | Takeda Pharms Usa |
| Fosrenol | US7381428 | Stabilized lanthanum carbonate compositions | Aug 26, 2024 | Takeda Pharms Usa |
| Fosrenol | US7465465 | Pharmaceutical formulation comprising lanthanum compounds | Aug 26, 2024 | Takeda Pharms Usa |
| Fosrenol | US8980327 | Capsule and powder formulations containing lanthanum compounds | Dec 01, 2030 | Takeda Pharms Usa |
| Fosrenol | US9023397 | Capsule and powder formulations containing lanthanum compounds | Dec 01, 2030 | Takeda Pharms Usa |
Coming Soon
Patent Strength Analyzer
YesNo
Thank you for your response 🥳
Lanthanum Carbonate Generics
Several generic applications have been filed for Lanthanum Carbonate. The first generic version for Lanthanum Carbonate was by Natco Pharma Ltd and was approved on Aug 11, 2017. And the latest generic version is by Barr Laboratories Inc A Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc and was approved on Jan 27, 2022.
Given below is the list of companies who have filed for Lanthanum Carbonate generic.
1. INVAGEN PHARMS
Invagen Pharmaceuticals Inc has filed for 3 different strengths of generic version for Lanthanum Carbonate. Given below are the details of the strengths of this generic introduced by Invagen Pharms.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 1GM BASE | tablet, chewable | Prescription | ORAL | AB | Jan 24, 2022 |
| EQ 500MG BASE | tablet, chewable | Prescription | ORAL | AB | Jan 24, 2022 |
| EQ 750MG BASE | tablet, chewable | Prescription | ORAL | AB | Jan 24, 2022 |
2. BARR
Barr Laboratories Inc A Wholly Owned Sub Of Teva Pharmaceuticals Usa Inc has filed for 3 different strengths of generic version for Lanthanum Carbonate. Given below are the details of the strengths of this generic introduced by Barr.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 750MG BASE | tablet, chewable | Prescription | ORAL | AB | Jan 27, 2022 |
| EQ 500MG BASE | tablet, chewable | Prescription | ORAL | AB | Jan 27, 2022 |
| EQ 1GM BASE | tablet, chewable | Prescription | ORAL | AB | Jan 27, 2022 |
3. NATCO PHARMA LTD
Natco Pharma Ltd has filed for 3 different strengths of generic version for Lanthanum Carbonate. Given below are the details of the strengths of this generic introduced by Natco Pharma Ltd.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| EQ 500MG BASE | tablet, chewable | Prescription | ORAL | AB | Aug 11, 2017 |
| EQ 750MG BASE | tablet, chewable | Prescription | ORAL | AB | Aug 11, 2017 |
| EQ 1GM BASE | tablet, chewable | Prescription | ORAL | AB | Aug 11, 2017 |